WINNIPEG, Manitoba, Canada – December 1st, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce the presentation of new compelling Type 2 diabetes data from studies of DM-204 at the Windhover Therapeutic Area Partnership Conference in Boston, MA, USA.

In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Treatment with DM-204 resulted in statistically significant lower mean differences compared to untreated animals after 21 days for the following parameters:

WINNIPEG, Manitoba, Canada – October 27, 2011 – DiaMedica Inc. (TSX-V: DMA) a biopharmaceutical company focused on the development of novel treatments for Type 1 and Type 2 diabetes announces the appointment of Dr. Paul Burn to DiaMedica’s Scientific Advisory Board. Dr. Burn currently serves as the Broin Chair and Director for The Sanford Project, an emerging translational research center focused on identifying and delivering a cure for Type 1 diabetes.

WINNIPEG, Manitoba, Canada – October 6, 2011 – DiaMedica Inc. (TSX-V: DMA) a biopharmaceutical company focused on the development of novel treatments for diabetes announces that the Company has received the 2011 Emerging Company of the Year Award from the Life Science Association of Manitoba (LSAM). The Life Science Association of Manitoba represents the provinces biotechnology, pharmaceutical, medical device and health products industries.

WINNIPEG, Manitoba – September 23, 2011 – DiaMedica Inc. (“DiaMedica”) (TSX-V:DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual and Special General Meeting (the “AGM”) of shareholders of DiaMedica dated September 22, 2011 David Allan, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were elected as the board of directors of the Corporation.